Cargando…

Experimental and In Silico Analysis of Cordycepin and its Derivatives as Endometrial Cancer Treatment

The aim of this study was to investigate the inhibition effects of cordycepin and its derivatives on endometrial cancer cell growth. Cytotoxicity MTT assays, clonogenic assays, and flow cytometry were used to observe the effects on apoptosis and regulation of the cell cycle of Ishikawa cells under v...

Descripción completa

Detalles Bibliográficos
Autores principales: Fong, Pedro, Ao, Cheng N., Tou, Kai I., Huang, Ka M., Cheong, Chi C., Meng, Li R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cognizant Communication Corporation 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848235/
https://www.ncbi.nlm.nih.gov/pubmed/29673423
http://dx.doi.org/10.3727/096504018X15235274183790
_version_ 1783645089086570496
author Fong, Pedro
Ao, Cheng N.
Tou, Kai I.
Huang, Ka M.
Cheong, Chi C.
Meng, Li R.
author_facet Fong, Pedro
Ao, Cheng N.
Tou, Kai I.
Huang, Ka M.
Cheong, Chi C.
Meng, Li R.
author_sort Fong, Pedro
collection PubMed
description The aim of this study was to investigate the inhibition effects of cordycepin and its derivatives on endometrial cancer cell growth. Cytotoxicity MTT assays, clonogenic assays, and flow cytometry were used to observe the effects on apoptosis and regulation of the cell cycle of Ishikawa cells under various concentrations of cordycepin, cisplatin, and combinations of the two. Validated in silico docking simulations were performed on 31 cordycepin derivatives against adenosine deaminase (ADA) to predict their binding affinities and hence their potential tendency to be metabolized by ADA. Cordycepin has a significant dose-dependent inhibitory effect on cell proliferation. The combination of cordycepin and cisplatin produced greater inhibition effects than did cordycepin alone. Apoptosis investigations confirmed the ability of cordycepin to induce the apoptosis of Ishikawa cells. The in silico results indicate that compound MRS5698 is least metabolized by ADA and has acceptable drug likeness and safety profiles. This is the first study to confirm the cytotoxic effects of cordycepin on endometrial cancer cells. This study also identified cordycepin derivatives with promising pharmacological and pharmacokinetic properties for further investigation in the development of new treatments for endometrial cancer.
format Online
Article
Text
id pubmed-7848235
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Cognizant Communication Corporation
record_format MEDLINE/PubMed
spelling pubmed-78482352021-02-16 Experimental and In Silico Analysis of Cordycepin and its Derivatives as Endometrial Cancer Treatment Fong, Pedro Ao, Cheng N. Tou, Kai I. Huang, Ka M. Cheong, Chi C. Meng, Li R. Oncol Res Article The aim of this study was to investigate the inhibition effects of cordycepin and its derivatives on endometrial cancer cell growth. Cytotoxicity MTT assays, clonogenic assays, and flow cytometry were used to observe the effects on apoptosis and regulation of the cell cycle of Ishikawa cells under various concentrations of cordycepin, cisplatin, and combinations of the two. Validated in silico docking simulations were performed on 31 cordycepin derivatives against adenosine deaminase (ADA) to predict their binding affinities and hence their potential tendency to be metabolized by ADA. Cordycepin has a significant dose-dependent inhibitory effect on cell proliferation. The combination of cordycepin and cisplatin produced greater inhibition effects than did cordycepin alone. Apoptosis investigations confirmed the ability of cordycepin to induce the apoptosis of Ishikawa cells. The in silico results indicate that compound MRS5698 is least metabolized by ADA and has acceptable drug likeness and safety profiles. This is the first study to confirm the cytotoxic effects of cordycepin on endometrial cancer cells. This study also identified cordycepin derivatives with promising pharmacological and pharmacokinetic properties for further investigation in the development of new treatments for endometrial cancer. Cognizant Communication Corporation 2019-02-05 /pmc/articles/PMC7848235/ /pubmed/29673423 http://dx.doi.org/10.3727/096504018X15235274183790 Text en Copyright © 2019 Cognizant, LLC. http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is licensed under a Creative Commons Attribution-NonCommercial NoDerivatives 4.0 International License.
spellingShingle Article
Fong, Pedro
Ao, Cheng N.
Tou, Kai I.
Huang, Ka M.
Cheong, Chi C.
Meng, Li R.
Experimental and In Silico Analysis of Cordycepin and its Derivatives as Endometrial Cancer Treatment
title Experimental and In Silico Analysis of Cordycepin and its Derivatives as Endometrial Cancer Treatment
title_full Experimental and In Silico Analysis of Cordycepin and its Derivatives as Endometrial Cancer Treatment
title_fullStr Experimental and In Silico Analysis of Cordycepin and its Derivatives as Endometrial Cancer Treatment
title_full_unstemmed Experimental and In Silico Analysis of Cordycepin and its Derivatives as Endometrial Cancer Treatment
title_short Experimental and In Silico Analysis of Cordycepin and its Derivatives as Endometrial Cancer Treatment
title_sort experimental and in silico analysis of cordycepin and its derivatives as endometrial cancer treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848235/
https://www.ncbi.nlm.nih.gov/pubmed/29673423
http://dx.doi.org/10.3727/096504018X15235274183790
work_keys_str_mv AT fongpedro experimentalandinsilicoanalysisofcordycepinanditsderivativesasendometrialcancertreatment
AT aochengn experimentalandinsilicoanalysisofcordycepinanditsderivativesasendometrialcancertreatment
AT toukaii experimentalandinsilicoanalysisofcordycepinanditsderivativesasendometrialcancertreatment
AT huangkam experimentalandinsilicoanalysisofcordycepinanditsderivativesasendometrialcancertreatment
AT cheongchic experimentalandinsilicoanalysisofcordycepinanditsderivativesasendometrialcancertreatment
AT menglir experimentalandinsilicoanalysisofcordycepinanditsderivativesasendometrialcancertreatment